Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, after the market closes on Wednesday, August 7, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Amphastar Pharmaceuticals, Inc.（納斯達克：AMPH）宣佈，公司將於2024年8月7日星期三美國太平洋時間下午2:00公佈截至2024年6月30日的第二季度業績，並舉行電話會議討論其財務結果。
To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
要參加電話會議，請在會議開始前十分鐘撥打免費電話號碼877-407-0989，國際電話號碼爲201-389-0921。
The call can also be accessed on the Investors page on the Company's website . The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
電話會議也可在公司網站的投資者頁面上獲取。會議的網絡直播重播將於直播電話會議結束後24小時內在公司網站上提供。
Company Information
公司信息
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at .
Amphastar是一家生物製藥公司，主要專注於開發、製造、營銷和銷售技術難度高的通用和專利注射、吸入和鼻內製品，此外，還銷售胰島素活性成分產品。公司的大多數成品產品用於醫院或急診治療和主要通過集團採購組織和藥品批發商簽訂合同並分銷。更多信息和資源可在網站上獲得。
Forward Looking Statements
前瞻性聲明
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the prospective benefits of the acquisition of BAQSIMI, including its potential for continued revenue growth, the success of our integration of BAQSIMI, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 10, 2024. In particular, there can be no guarantee that the acquisition of BAQSIMI will be beneficial to our business, that any event, change or other circumstance could cause the results of the acquisition and integration of BAQSIMI into our product portfolio to differ from Amphastar's expectation, that all or any of the contingent consideration will be payable on the terms described herein or at all, or that Amphastar can reliably predict the impact of BAQSIMI on its financial results or financial guidance. You can locate these reports through our website at and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
本新聞稿及上述電話會議中所有陳述中涉及的信息都屬於前瞻性陳述，包括但不限於有關我們對未來財務表現和業務趨勢、公司的未來增長、產品的銷售和營銷、市場規模和擴張、產品組合、產品開發、包括ANP的DMF的FDA申報或批准的時間、產品上市的時間、收購以及與我們的產品候選者流水線有關的其他事項的期望。一些陳述並非事實，而是基於Amphastar的歷史表現以及我們對業務、運營和其他類似或相關因素的當前預期、估計和投影。雖然並非所有前瞻性陳述都包含這些單詞，但這些單詞，如“可能”“或許”“將”“能夠”“或者”“應該”“預計”“潛在”“繼續”“期望”“打算”“計劃”“項目”“相信”“估計”以及其他類似或相關的表達，被用於識別這些前瞻性陳述。您不應該過度依賴前瞻性陳述，因爲它們涉及已知和未知的風險、不確定性和假設，這些風險、不確定性和假設很難或不可能預測，並且在某些情況下超出Amphastar的控制。實際結果可能因多種因素而有所不同，這些因素在Amphastar向證券交易委員會提交的文件中進行了描述，包括我們於2024年2月29日向證券交易委員會提交的2013年年度報告（Form 10-k）和我們於2024年5月10日向證券交易委員會提交的截至2024年3月31日的季度報告（Form 10-Q）。特別是，不能保證收購BAQSIMI將對我們的業務有益，任何事件、變化或其他情況都可能導致收購和將BAQSIMI整合到我們的產品組合中的結果與Amphastar的預期不同，也不能保證按照此處描述的條款支付所有或任何待定的考慮，或者Amphastar能夠可靠地預測BAQSIMI對其財務結果或財務指引的影響。您可以通過我們的網站和SEC網站找到這些報告。本新聞稿中的前瞻性陳述僅針對發佈日期。即使有新的信息公佈，或者有後續事件導致我們的預期發生變化，Amphastar也不承擔修訂或更新信息或任何前瞻性陳述的責任，無論是本新聞稿還是上述電話會議。
Contact:
聯繫方式：
Bill Peters
Chief Financial Officer
(909) 476-3416
Bill Peters
致富金融(臨時代碼)
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
信息來源：Amphastar Pharmaceuticals, Inc。
譯文內容由第三人軟體翻譯。